Comparing two bone-strengthening drug schedules for osteoporosis
Part of Bones, joints & muscles, Hormones & metabolism clinical trials.
This trial tests whether switching between two medications (Romosozumab and Denosumab) using a cycle or sequence schedule works better for improving bone density in postmenopausal women with severe osteoporosis. It aims to find the most effective treatment plan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 50 to 90 who has gone through menopause
- You have a bone density T-score of -3.0 or lower in your spine
- You have not had any osteoporosis treatment in the last 2 years
- You are not allergic to Romosozumab or Denosumab
- You do not have certain health issues like autoimmune disease, cancer, heart disease, or kidney problems
- You are not a heavy smoker (more than one pack per day) and do not have planned dental surgeries this year
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two osteoporosis drugs (romosozumab and denosumab) given alone or together to see which works better for improving bone density. It may help if you are a postmenopausal woman with osteoporosis and have not taken strong bone medications recently.
This study compares two medicines (ibandronate and zoledronic acid) to see which one works better at keeping bones strong after stopping denosumab (Prolia). It's for postmenopausal women with mild to moderate bone thinning.
This trial tests if it's safe to switch from a long-term osteoporosis medication called Prolia to another treatment. It may help women and men who have been on Prolia for at least 3 years.
This trial is testing a medicine called romosozumab to treat postmenopausal women with severe osteoporosis and a recent fracture. It aims to find the best way to use this drug to strengthen bones and prevent more fractures.
This study looks at what medicine works best for women who have finished a 1-year course of a strong bone-building drug (romosozumab or teriparatide) for severe osteoporosis. The goal is to find a good follow-up treatment to keep bones strong and prevent fractures.
This study tests a combination of two bone-building drugs (romosozumab and teriparatide) in postmenopausal women with osteoporosis who are at high risk for fractures. The goal is to see if the combination strengthens bones faster and better than either drug alone.
Hear when a new Osteoporosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.